Pharmacokinetics and Relative Bioavailability of Ambroxol Hydrochloride Aerosol and Injection
American Journal of Clinical and Experimental Medicine
Volume 3, Issue 6, November 2015, Pages: 368-371
Received: Dec. 24, 2015;
Published: Dec. 30, 2015
Views 5042 Downloads 273
Jing Zhang, School of Pharmacy, Inner Mongolia Medical University, Hohhot, China
Na Yi, School of Pharmacy, Inner Mongolia Medical University, Hohhot, China
Lidao Bao, School of Pharmacy, Inner Mongolia Medical University, Hohhot, China; Department of Pharmacy, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China
Tengfei Yu, School of Pharmacy, Inner Mongolia Medical University, Hohhot, China
Follow on us
To compare the pharmacokinetics and relative bioavailability of ambroxol hydrochloride (AH) aerosol and injection, the volunteers were subjected to single-dose crossover inhalation (injection) of 100 mg AH aerosol (injection). The drug concentrations in plasma were determined by HPLC. The areas under curve (AUC) of the two formulations were compared by the three-factor analysis of variance and the bi-directional one-side t test. The Cmax, tmax, t1/2β and AUC values of the aerosol group and the injection group were (154.75±26.12) and (157.39±26.09) ng/ml, (1.12±0.34) and (1.29±0.33) h, (6.98±1.62) and (7.75±1.26) h, and (1593.02±290.45) and (1438±132.46) h•ng/ml, respectively. The bioavailabilities of AH aerosol and injection were the same, and the relative bioavailability of the aerosol was (96.52±11.44)%.
Ambroxol Hydrochloride, Bioavailability, Pharmacokinetics, HPLC
To cite this article
Pharmacokinetics and Relative Bioavailability of Ambroxol Hydrochloride Aerosol and Injection, American Journal of Clinical and Experimental Medicine.
Vol. 3, No. 6,
2015, pp. 368-371.
Hayashi K, Hosoe H, Kaise T, Ohmori K (2000) Protective effect of erdosteine against hypochlorous acid-induced acute lung injury and lipopolysaccharide-induced neutrophilic lung inflammation in mice. J Pharm Pharmacol 52(11): 1411-1416.
Wiessmann KJ, Niemeyer K (1978) [Clinical results in the treatment of chronic obstructive bronchitis with ambroxol in comparison with bromhexine (author's transl)]. Arzneimittelforschung 28(5a): 918-921.
Lee HJ, Joung SK, Kim YG, Yoo JY, Han SB (2004) Bioequivalence assessment of ambroxol tablet after a single oral dose administration to healthy male volunteers. Pharmacol Res 49(1): 93-98.
Ren YC, Wang L, He HB, Tang X (2009) Pulmonary selectivity and local pharmacokinetics of ambroxol hydrochloride dry powder inhalation in rat. J Pharm Sci 98(5): 1797-1803.
Ballantyne BT, O'Hare SJ, Paschall JL, et al. (1993) Electromyographic activity of selected shoulder muscles in commonly used therapeutic exercises. Phys Ther 73(10): 668-677; discussion 677-682.
Amantea M, Newman MS, Sullivan TM, Forrest A, Working PK (1999) Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs. Hum Exp Toxicol 18(1): 17-26.
Rutland BE, Nachreiner RF, Kruger JM (2009) Optimal testing for thyroid hormone concentration after treatment with methimazole in healthy and hyperthyroid cats. J Vet Intern Med 23(5): 1025-1030.
Yuen O, Caligiuri MP, Williams R, Dickson RA (1996) Tardive dyskinesia and positive and negative symptoms of schizophrenia. A study using instrumental measures. Br J Psychiatry 168(6): 702-708.
Cerretani D, Roviello F, Pieraccini M, et al. (2002) Pharmacokinetics of intraarterial mitomycin C in hypoxic hepatic infusion with embolization in the treatment of liver metastases. Vascul Pharmacol 39(1-2): 1-6.
Villacampa J, Alcántar F, Rodríguez JM, Morales JM, Herrera J, Rosete R (2003) Pharmacokinetic properties of single-dose loratadine and ambroxol alone and combined in tablet formulations in healthy men. Clin Ther 25(8): 2225-2232.